Table 2.
Parameter | Estimate (per 12-week cycle)a | Reference |
---|---|---|
Mortality | ||
All-cause | Age, gender-specific | 3 |
HIVb | 0.9% | 4 |
AIDSb | 3.5% | 4 |
Acute kidney injury | 26.6% | 5 |
Chronic kidney disease with dialysisc | 1.9% | 6 |
Probability of AIDS, given nonsuppressive regimens | 1.8% | 10 |
CD4 <50 cells/mm3 (%, among patients with AIDS)d | 55.2% | 11 |
Proportion achieving virologic response, mean (range per 12-week cycle) | ||
First-line | ||
Atripla® | 0.81 (0.28–0.72) | 20,21 |
Stribild™ | 0.85 (0.76–0.89) | 20,21 |
Second-line | 0.49 (0.41–0.57) | 22,23 |
Third-line | 0.51 (0.49–0.57) | 10,24,25 |
Change in CD4 count, mean (range per 12-week cycle) | ||
First-line | ||
Atripla | 263 (120–367) | 2,7,8,9,21 |
Stribild | 263 (140–426) | 2,7,8,9,21 |
Second-line | 105 (94–109) | 7,8,9,26,27 |
Third-line | 129 (79–147) | 7,8,9,10,24,25 |
Notes:
Values are rounded;
excess mortality in addition to all-cause;
average annual mortality by race weighted using Stribild population distribution;
CD4 count ≤200 cells/mm3 among all patients with AIDS.
Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus.